Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography

Synapse

Volumn 49, Issue 4, 2003, Pages 209-215

  Seeman, Philip ^a,b,c   Tallerico, Teresa ^b   Ko, Françoise ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE   (Canada)

Author keywords

Amphetamine; Antipsychotics; Brain imaging; High affinity state of D2

Indexed keywords

AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; DOMPERIDONE; DOMPERIDONE H 3; DOPAMINE; DOPAMINE 2 HIGH RECEPTOR; DOPAMINE 2 LONG RECEPTOR; DOPAMINE 2 RECEPTOR; METHYLSPIPERONE C 11; RACLOPRIDE; RACLOPRIDE C 11; RACLOPRIDE H 3; SPIPERONE; SPIPERONE H 3; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; ISOTONIC SOLUTION; SODIUM; TRITIUM;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN HOMOGENATE; CELL MEMBRANE; CONTROLLED STUDY; CORPUS STRIATUM; CULTURE MEDIUM; DISSOCIATION CONSTANT; HUMAN; HUMAN TISSUE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; ANIMAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM;

ANIMALS; DOMPERIDONE; DOPAMINE; DOPAMINE ANTAGONISTS; ISOTONIC SOLUTIONS; RACLOPRIDE; RATS; RECEPTORS, DOPAMINE D2; SODIUM; SPIPERONE; TOMOGRAPHY, EMISSION-COMPUTED; TRITIUM;

EID: 0043269348     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10232     Document Type: Article

References (41)

1. Aalto S, Hirvonen J, Kajander J, Scheinin H, Någren K, Vilkman H, Gustafsson L, Syvälahti E, Hietala J. 2002. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology 164:401-406.
2. 3H-Domperidone: a selective ligand for dopamine receptors. Naunyn Schmied Arch Pharmacol 308:231-237.
3. Breier A, Su TP, Malhotra AK, Elman I, Adler CM, Weisenfeld NI, Pickar D. 1999. Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders. Neuropsychopharmacology 20:340-345.
4. Chio CL, Lajiness ME, Huff RM. 1994. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 45:51-60.
5. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. 1985. The functional state of the dopamine receptor in the anterior pituitary is in the high-affinity form. Endocrinology 117:690-697.
6. 3H]-Domperidone labels only a single population of receptors which convert from high to low affinity for dopamine in rat brain. Naunyn Schmied Arch Pharmacol 332:21-25.
7. Grünewald S, Reiländer H, Michel H. 1996. In vivo reconstitution of dopamine D2S receptor-mediated G protein activation in baculovirus-infected cells: preferred coupling to Gi1 versus Gi2. Biochemistry 35:15162-15173.
8. Hall H, Wedel I. 1986. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum. Acta Pharmacol Toxicol 58:368-373.
9. Hamblyn MW, Leff SE, Creese I. 1984. Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Biochem Pharmacol 33:877-887.
10. Huff RM, Molinoff PB. 1982. Quantitative determination of dopamine receptor subtypes not linked to activation of adenylate cyclase in rat striatum. Proc Natl Acad Sci USA 79:7561-7565.
11. 3H]neuroleptic binding. Eur J Pharmacol 144:163-171.
12. Kapur S. 2003. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13-23.
13. Kawagoe KT, Garris PA, Wiedemann DJ, Wightman RM. 1992. Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 51:55-64.
14. Ko F, Seeman P, Sun WS, Kapur S. 2002. Dopamine D2 receptors internalize in their low-affinity state. NeuroReport 13:1017-1020.
15. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cerebral Blood Flow Metab 20:423-451.
16. 3H]spiperone. Eur J Pharmacol 81:273-285.
17. Leonard MN, Halliday CA, Marriott AS, Strange PG. 1988. D2 dopamine receptors in rat striatum are homogeneous as revealed by ligand-binding studies. Biochem Pharmacol 37:4335-4339.
18. Liu IS, George SR, Seeman P. 2000. The human dopamine D2(Longer) receptor has a high-affinity state and inhibits adenylyl cyclase. Mol Brain Res 77:281-284.
19. 3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides. J Pharmacol Exp Ther 274:790-797.
20. 35S] binding. J Pharmacol Exp Ther 285:119-126.
21. 3H-domperidone binding on striatal dopamine receptors. Life Sci 23:1781-1784.
22. 3H]raclopride binding to the dopamine D2 receptor. Arch Pharm Res 23:360-366.
23. 2(short) dopamine receptor. J Neurochem 82:1106-1117.
24. Perachon S, Schwartz JC, Sokoloff P. 1999. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. Eur J Pharmacol 366:293-300.
25. Richfield EK, Young AB, Paenney JB. 1986. Properties of D2 dopamine receptor autoradiography: high percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections. Brain Res 383:121-128.
26. Seeman P. 2002. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38.
27. Seeman P, Kapur S. 2000. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 97:7673-7675.
28. 3H]quinpirole. Eur J Pharmacol 203:105-109.
29. Seeman P, Van Tol HH. 1995. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol. 291:59-66.
30. 3H]spiperone depend on tissue concentration: analysis and examples. J Neurochem 43:221-235.
31. Seeman P, Watanabe M, Grigoriadis D, Tedesco JL, George SR, Svensson U, Nilsson JLG, Neurneyer JL. 1985. Dopamine D2 receptor binding sites for agonists. A tetrahedral model. Mol Pharmacol 28:391-399.
32. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3:96-97.
33. 2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. Eur J Pharmacol 227:139-146.
34. Seeman P, Tallerico T, Ko F, Tenn C, Kapur S. 2002. Amphetaminesensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 46:235-239.
35. Sokoloff P, Andrieux M, Besançon R, Pilon C, Martres M-P, Giros B, Schwartz J-C. 1992. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur J Pharmacol 225:331-337.
36. 3 dopamine receptors in a range of tissues and under different conditions. J Neurochem 64:940-943.
37. Volkow ND, Wang G-J, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, MacGregor R, Burr G, Cooper T, Wolf AP. 1994. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 16:255-262.
38. Watanabe M, George SR, Seeman P. 1985. Dependence of dopamine receptor conversion from agonist high- to low-affinity state on temperature and sodium ions. Biochem Pharmacol 34:2459-2463.
39. Wiens BL, Nelson CS, Neve KA. 1998. Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. Mol Pharmacol 54:435-444.
40. Wong DF, Gjedde A, Reith J, Grunder G, Szymanski S, Yokoi F, Hong C, Nestadt G, Neufeld K, Pearlson G, Tune L, Angrist B. 1997. Imaging intrasynaptic, postsynaptic and presynaptic dopamine dysfunction in psychosis. Soc Neurosci Abstr 23:555.1.
41. Zawarynski P, Tallerico T, Seeman P, Lee SP, O'Dowd BF, George SR. 1998. Dopamine D2 receptor dimers in human and rat brain. FEBS Lett 441:383-386.